Sputnik V vaccine is 92% effective against coronavirus, says Russia

Author : Saipriya Iyer | Published Date : 2020-11-13 

Russia’s Sovereign Wealth Fund on Wednesday stated that its Sputnik V COVID-19 vaccine is 92% effective at safeguarding people from getting infected with coronavirus, as per the interim trial results. The Russian government reportedly announced this metric as it rushes to keep up with the Western vaccine developers that are competing to develop effective vaccine.

The initial outcomes are only the second ones to be unveiled from a late stage human clinical study in the ongoing global competition to create a vaccine that would stop the pandemic, which has severely affected the world’s economy and more importantly, killed 1.2 million people.

In August, Russia had registered its vaccine for public use, becoming the first nation to do so. However, the approval came prior to the beginning of the vaccine’s large scale trial in September.

The interim outcomes are based upon data from over 16,000 initial clinical trial participants who were given both shots of Sputnik V, a two-dose vaccine, claims the RDIF (Russian Direct Investment Fund), who has been backing and marketing the vaccine across the world.

The so-called Phase 3 clinical trial of the two dose vaccine formulated by the Gamaleya Institute would be conducted across 29 clinics in Moscow, enrolling approximately 40,000 volunteers, of which a quarter would get a placebo shot.

RDIF added that the chances of people getting infected by COVID-19 were 92% less in people who were dosed with Sputnik V in comparison to those who were given placebo. The number is well above the 50% effectiveness target set by the U.S. FDA (Food and Drug Administration) for a potential vaccines.

The Sputnik V is developed to activate a response using two shots given 21 days apart, each dependent upon different viral vectors that generally cause common cold: human adenoviruses Ad26 and Ad5.

Source credit: https://uk.reuters.com/article/health-coronavirus-russia-vaccine/russia-says-its-sputnik-v-covid-19-vaccine-is-92-effective-idUKL1N2HW1RN

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

Ramping production of lithium-ion batteries to accelerate tert-amylbenzene demand in Asia Pacific

Published Date: 2021-01-05         Author: Saipriya Iyer

As an active pharmaceutical ingredient (API) used in various clinical products to being used as an electronic additive in the making of lithium-ion batteries, tert amylbenzene (TAB) has gained wide-spread recognition across diverse industries. The chemical substance acts as a crucial intermediate in... Read More

FMCG firms to explore oral care market amidst rising hygiene concerns

Published Date: 2021-01-04         Author: Saipriya Iyer

Fast-moving consumer goods businesses in India are reportedly expanding their range of oral care, joining new and niche categories including mouthwashes, ayurvedic mouth cleansers, and mouth sprays as customer issues around general hygiene persists. For the record, Dabur India and Colgate Palmoli... Read More

Microsoft to introduce ‘Google assistant’ alternative for Windows

Published Date: 2020-12-28         Author: Saipriya Iyer

Microsoft Corporation, an American multinational technology giant, is reportedly testing a new voice launcher feature which will enable users to interact with files and applications using voice commands. According to trusted sources, the feature is currently available to select group of users who... Read More

© 2021 Fractovia. All Rights Reserved